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Abstract
The fatty liver index (FLI) predicts fatty liver by using BMI, waist circumference, γ-glutamyl-
transferase and triglycerides. We investigated the association between the FLI and the risk
of type 2 diabetes and evaluated to what extent single FLI components contribute to the dia-
betes risk. We analysed a case-cohort study (random sub-cohort: 1922; incident cases:
563) nested within the European Prospective Investigation into Cancer and Nutrition
(EPIC)-Potsdam study. The proportion of exposure effect (PEE) explained by single FLI
components was evaluated and effect decomposition using inverse probability weighting
(IPW) was applied. Women and men with a FLI60 compared to those with a FLI <30 had
a multivariable-adjusted Hazard Ratio (HR) of 17.6; 95% confidence interval (CI) 11.1-28.0
and HR: 10.9; 95% CI 6.22-19.2, respectively. Adjustment for BMI or waist circumference
attenuated this association in men [PEEBMI(95% CI) = 53.8% (43.9%-65.8%); PEEwaist(95%
CI) = 54.8% (44.2%-68.8%)]. In women, adjustment for waist circumference attenuated the
association to a lesser degree than in men [PEEwaist(95% CI) = 31.1%; (21.9%-43.1%)]
while BMI had no appreciable effect [PEEBMI(95% CI) = 11.0% (2.68%-21.0%)]. γ-glutamyl-
transferase and triglycerides showed only a small attenuation in women [PEEGGT(95% CI)
= 3.11% (-0.72%-4.48%); PEETG(95% CI) = 6.36% (3.81%-9.92%)] and in men [PEEGGT =
0%; PEETG(95% CI) = 6.23% (2.03%-11.8%)]. In women, the total effect was decomposed
into a direct effect and 4 indirect effects (HRBMI= 1.10; HRwaist = 1.28; HRGGT = 0.97 and
HRTG= 1.03). In men, the 4 indirect effects were HRBMI= 1.25; HRwaist = 1.29; HRGGT = 0.97
and HRTG= 0.99. These data suggest that the FLI, as a proxy for fatty liver, is associated
with risk of type 2 diabetes. This association is only partly explained by standard estimates
of overall and abdominal body fatness, particularly among women.
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Introduction
Non-alcoholic fatty liver disease (NAFLD) is characterized by increased fat storage in form of
triglycerides in the liver (exceeding 5% of its weight) and the absence of excessive alcohol con-
sumption [1]. NAFLD is strongly linked to obesity, dyslipidemia, and insulin resistance and is
therefore considered as the hepatic manifestation of metabolic syndrome [2]. In a large case-
control study, patients suffering from type 2 diabetes had 80% more liver fat than age-, sex-
and body weight-matched controls [3]. Furthermore, changes in liver fat content might modify
the risk of type 2 diabetes. Within this context, the progression of fatty liver during a 5-year fol-
low-up was associated with an increased risk of type 2 diabetes—independent of baseline BMI,
changes in BMI over time as well as baseline blood glucose and insulin [4].
The gold standard for the diagnosis of NAFLD is liver biopsy [5]. However, this procedure
is not suitable in all NAFLD-patients and its usage can lead to complications [6]. Therefore,
non-invasive techniques like magnetic resonance spectroscopy (MRS), computed tomography
(CT) and ultrasound are often used for diagnosing fatty liver in epidemiological studies. While
MRS is very sensitive in detecting lower degrees of hepatic fat, ultrasound and CT provide rath-
er semi-quantitative measurements [7]. Furthermore, these methods are associated with high
costs and are therefore usually not suitable in a large population-based screening of fatty liver.
Thus, alternative estimates of NAFLD based on routine risk factors have been proposed. For
example, Bedogni et al. developed a simple algorithm for predicting fatty liver based on ultraso-
nography in 496 individuals in 2006 [8]. The fatty liver index (FLI) consists of body mass index
(BMI), waist circumference, γ-glutamyltransferase (GGT) and triglycerides. This index was
validated against MRS in a German population and provided moderate diagnostic accuracy
[area under the receiver operating characteristic curve (AUROC) = 0.72; 95% CI 0.59–0.92]
[9]. Up to now, only two previous studies evaluated the association between FLI and incident
diabetes, in a French and a Korean population [10, 11]. However, the FLI includes BMI and
waist circumference in its computation, two major anthropometric risk factors of type 2 diabe-
tes, and it remains unclear to which extent single components of the FLI contribute to the risk
association and whether the FLI predicts diabetes beyond routine measures of body fat.
Therefore, the aim of this study was to evaluate whether fatty liver estimated by FLI is asso-
ciated with risk of type 2 diabetes within the EPIC-Potsdam study. Furthermore, we deter-
mined to what extent this association is attributable to its single components.
Methods
Study population
The European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam study
consists of 27,548 participants (16,644 women and 10,904 men) recruited between 1994 and
1998 from the general population in Potsdam and surroundings. The baseline examination in-
volved a personal interview including questions on prevalent diseases, a self-administered
questionnaire on socio-economic and lifestyle characteristics, interviewer-conducted anthro-
pometric measurements and a blood sample collection [12, 13]. To evaluate biochemical risk
factors for type 2 diabetes, a prospective case-cohort study within the EPIC-Potsdam study was
designed, described in detail previously [14]. From 26,444 participants who provided blood
samples at baseline, 2,500 individuals were randomly selected. We excluded individuals with
liver cancer (n = 1), liver medication (n = 7) and medication for treating hyperlipidemia
(n = 187), as well as participants with missing data on biomarker measurements (n = 356). Fur-
ther exclusion criteria were implausible energy intake (<800 or>6000 kcal/day), prevalent dia-
betes and participants with uncompleted follow-up questionnaires, leaving 1922 individuals
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(1215 women and 707 men) for analyses in the sub-cohort. Identical exclusion criteria were ap-
plied for type 2 diabetes cases, leaving 563 incident cases (224 women and 339 men; overlap of
24 women and 33 men within the sub-cohort due to the case-cohort design).
Ethics statement
All participants provided written informed consent and permission was given by the ethics
committee of the State of Brandenburg, Germany.
FLI as a surrogate measure of fatty liver
The FLI was developed in an Italian population aged 18 to 75 years old (61% males) including
216 individuals with and 280 individuals without suspected liver disease [8]. Within this popu-
lation, the presence of fatty liver was identified by using ultrasound. Bedogni et al. used boot-
strapped stepwise logistic regression to derive the final score [8]. Out of 13 variables (including
gender, age, ethanol intake, alanine transaminase, aspartate transaminase, GGT, BMI, waist
circumference, sum of 4 skinfolds, glucose, insulin, triglycerides and cholesterol) four predic-
tors remained within the score:
FLI ¼ ðeð0:953lnðTGÞþ0:139BMIþ0:718lnðGGTÞþ0:053WC15:745ÞÞ=
ð1þ eð0:953lnðTGÞþ0:139BMIþ0:718lnðGGTÞþ0:053WC15:745ÞÞ  100
TG: triglycerides in mg/dl
GGT: γ-glutamyltransferase in U/l
WC: waist circumference in cm
The FLI ranges from 0 to 100 and in the population of Bedogni et al. a FLI<30 ruled out
and a FLI60 ruled in fatty liver with a good diagnostic accuracy (AUROC = 0.85; 95% CI
0.81–0.88).
Assessment of covariates
Socio-economic and lifestyle factors such as level of education, occupation, smoking behavior
and physical activity were assessed by a self-administered questionnaire and a personal inter-
view. Weight, height and waist circumference were measured at baseline by trained interview-
ers and followed standard protocols under strict quality control [15]. Body weight was
measured by electronic digital scales, accurate to 0.1 kg (Soehnle, type 7720/23, Murrhardt,
Germany). Individuals wore only light underwear and had emptied their bladder. Heights were
measured to the nearest 0.1 cm using a flexible anthropometer. Waist circumference was ob-
tained in the standing position with weight distributed equally over both feet. Waist circumfer-
ence was taken to the nearest 0.5 cm and measured with a non-stretching tape applied
horizontally midway between the lower rib margin and the superior anterior iliac spine [16].
Dietary intake during the last twelve months was assessed through a validated food frequency
questionnaire (FFQ) [17].
Determination of biomarkers
Biomarker measurement was conducted in blood samples stored at -80°C or lower until analy-
sis. Plasma levels of C-reactive protein (CRP), triglycerides, blood glucose, HDL-cholesterol,
total cholesterol, GGT, alanine transaminase (ALT), fetuin-A and erythrocyte levels of HbA1c
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were measured with the automatic ADVIA 1650 analyzer (Siemens Medical Solutions, Er-
langen, Germany) [14, 18]. For determination of fetuin-A, an immunoturbidimetric method
was used with specific polyclonal goat anti-human fetuin-A antibodies to human fetuin-A
(BioVendor Laboratory Medicine, Modreci, Czech Republic) [14]. Plasma adiponectin concen-
trations were determined through ELISA (Linco Research, St. Charles, MO, USA) [19]. All
assay procedures were performed according to the manufacturer’s description. LDL-cholester-
ol levels were calculated using the Friedewald equation [20].
Blood samples were drawn in monovettes containing citrate as anticoagulant. Therefore
plasma concentrations were multiplied by 1.16 for women and 1.17 for men in order to receive
levels for these citrate plasma samples comparable to levels obtainable from EDTA plasma [21].
Assessment of type 2 diabetes
Every 2–3 years follow-up questionnaires were sent out to identify incident cases of diabetes,
with response rates of>90% [22]. Incident type 2 diabetes was evaluated by a physician with
information from self-reported medical diagnoses, medication records, and dieting behavior.
Furthermore, additional information from death certificates or from random sources, such as a
tumor center, physician, or clinic, which provided assessments from other diagnoses, was ob-
tained. Although the self-reports of type 2 diabetes were generally reliable [23], all incident
cases were verified by treating physicians. They were asked to provide data on the date and
type of diagnosis, on diagnostic tests and the treatment in a questionnaire. Cases confirmed by
a physician (International Classification of Diseases, 10th Edition (ICD10): E11) and a diagno-
sis date after the baseline examination were considered as confirmed incident cases of type 2 di-
abetes. For the current analysis, we used data collected until the end of the fourth follow-up
period in August 2005.
Statistical analysis
Associations between the FLI and diabetes risk were evaluated using Cox regression modified
for the case-cohort design according to the Prentice method [24]. The proportional hazards as-
sumption was tested via plotting of the Schönfeld residuals [25]. Age was used as the underly-
ing time scale in all models, with entry time defined as the participant’s age at recruitment and
exit time defined as the age at the end of follow-up based on the date of diagnosis, death, or re-
turn of the last follow-up questionnaire. The analysis was stratified for age at the baseline ex-
amination in one-year intervals. Cox models were further adjusted for education (no
vocational training or in training, vocational training, technical school, technical college or uni-
versity), occupation (sedentary, standing, (heavy) manual work), smoking behavior (never
smoker, ex-smoker, current smoker<20 units/day, current smoker20 units/day), sport ac-
tivities (no sport,4 h/week,>4 h/week), biking (no biking,<2.5 h/week, 2.5–4.9 h/week,5
h/week), alcohol intake (no alcohol intake,>0–6 g/day;>6–12 g/day;>12–24 g/day;>24–60
g/day;>60–96 g/day;>96 g/day), coffee consumption (ml/day), red meat intake (g/day) and
intake of whole-grain bread (g/day). In sensitivity analyses, individuals with a daily alcohol
consumption of>30 g for men and>20 g for women were excluded [1]. Furthermore, we eval-
uated whether lifetime alcohol intake has an influence by excluding participants who were for-
mer heavy drinkers or consumed alcohol occasionally heavy or always heavy during their
lifetime [26]. In a third sensitivity analyses the study population was restricted to participants
who had fasted for at least eight hours or had not eaten but drunk within the past eight hours.
Finally, participants in a prediabetic state (HbA1c5.7) were excluded.
To evaluate the impact of single components within the FLI, the Cox models were further
adjusted for BMI, waist circumference, GGT or triglycerides at baseline. The proportion of
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exposure effect (PEE) [27] explained by FLI components was calculated:
PEE ¼ ½1 ðbadjusted=bcrudeÞ  100
95% conﬁdence intervals (CI) of PEE were estimated by bootstrapping method with a sampling
rate of 80% and 1000 replicates which was adapted for case-cohort design [28]. Furthermore,
differences in β-coefﬁcients with and without adjustment for anthropometry were tested one-
tailed for statistical signiﬁcance (according to [29]).
Mediation analysis was performed using the approach introduced by Lange et al. [30, 31].
This method relies on the counterfactual framework of mediation analysis [32] and provides
the possibility to decompose the total effect of a given exposure X on the outcome Y into a nat-
ural direct effect (X!Y) and a natural indirect effect through each mediator M (X!M!Y) by
using inverse probability weighting (IPW). In the present analysis, we considered the four FLI
components (BMI, waist circumference, GGT and triglycerides) as mediators of the association
between the FLI and risk of type 2 diabetes. However, one important assumption is that the
mediators should be independent from each other. This is difficult to fulfill when investigating
highly correlated factors such as BMI and waist circumference. Therefore, we further trans-
formed waist circumference by adding up the median waist circumference with the residuals
obtained from a linear regression of waist circumference and BMI adjusted for the same covari-
ates, used within the Cox regression. 95% CI for direct and indirect effects were obtained by
using a sampling rate of 80% and 1000 bootstrap replicates applied for case-cohort design [28].
All data analyses were performed by using the software package Statistical Analysis System
(SAS) Enterprise Guide 6.1 with SAS version 9.4 (SAS Institute Inc., Cary, NC, USA). We con-
sidered p<0.05 as being statistically significant.
Results
Table 1 represents the baseline characteristics for women and men according to categories of
the FLI. In higher FLI categories women were less educated and slightly more likely to perform
standing occupation or heavy manual work. However, women were less physically active dur-
ing their leisure time. There was no clear association between the FLI and smoking status in
women. Women in higher FLI categories consumed less alcohol. Men in the highest FLI cate-
gory were slightly older, less educated and more likely to be an ex-smoker. They were less phys-
ically active, consumed more red meat and less whole-grain bread and coffee. Contrary to
women, the alcohol consumption increased with higher FLI in men. BMI and waist circumfer-
ence were positively associated with the FLI in women and men.
Markers of dyslipidemia such as triglycerides and total cholesterol increased with higher
FLI, whereas HDL-cholesterol was inversely associated with the FLI. Liver enzymes (ALT,
GGT), fetuin-A and CRP increased with higher FLI. Adiponectin showed an inverse associa-
tion with higher FLI, whereas blood glucose and HbA1c showed slightly positive trends.
Hazard ratios (HR) for type 2 diabetes stratified by sex according to categories of the FLI are
shown in Table 2. Compared to women in the reference category, women in the top third FLI
category (60) had a HR of 17.1 (95% CI 11.3–25.9) in the age-stratified model. Adjustment
for lifestyle and other socioeconomic factors did not affect this association: HR 17.6 (95% CI
11.1–28.0).
Adjustment for BMI or waist circumference at baseline led to an attenuation of the associa-
tion between the FLI and risk of type 2 diabetes in women and men. In women, the strongest
attenuation was observed for waist circumference in the highest category [PEEwaist (95% CI) =
31.1% (21.9%–43.1%)], whereas BMI adjustment had only a small effect [PEEBMI (95% CI) =
11.0% (2.68%–21.0%)]. Inclusion of BMI and waist circumference simultaneously resulted in a
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similar attenuation of the association as waist circumference alone [PEEBMI + waist = 29.2%
(19.5%–41.3%)]. The inclusion of GGT or triglycerides within the model led to a weaker atten-
uation [PEEGGT (95% CI) = 3.11% (-0.72%–4.48%); PEETG (95% CI) = 6.36% (3.81%–9.92%)].
Table 1. Baseline characteristics by categories of the fatty liver index in EPIC-Potsdama.
FLI categories women FLI categories men
<30 30-<60 60 <30 30-<60 60
FLI, median (IQR) 7.17 (10.4) 42.5 (15.2) 77.0 (22.0) 16.8 (14.5) 44.0 (13.5) 78.2 (19.1)
n 878 175 162 201 222 284
age at baseline, median (IQR) 45.0 (15.0) 55.0 (14.0) 53.0 (16.0) 51.0 (14.0) 51.0 (15.0) 52.0 (14.0)
Education, %
no vocational training/ in training/ vocational training 36.2 51.4 50.6 25.4 35.1 33.8
technical school 29.8 22.9 33.3 15.9 12.6 19.4
technical college or university 33.9 25.7 16.1 58.7 52.3 46.8
Occupation, %
sedentary occupation 64.6 58.3 55.6 58.2 55.0 55.6
standing occupation 32.5 38.9 38.9 32.8 32.0 32.0
(heavy) manual work 2.96 2.86 5.56 8.96 13.1 12.3
Smoking status, %
never smoker 58.5 55.4 54.9 38.3 33.8 24.7
ex-smoker 23.9 25.1 29.0 34.3 40.5 50.7
smoker <20 units/day 14.6 13.1 13.6 16.4 13.5 15.9
smoker 20 units/day 2.96 6.29 2.47 11.0 12.2 8.80
physical activity, median (IQR)b 2.00 (4.00) 1.50 (3.50) 1.00 (3.00) 2.00 (4.50) 2.00 (4.00) 1.00 (3.75)
alcohol intake in g/day, median (IQR) 5.52 (8.91) 4.63 (9.62) 4.23 (8.10) 14.8 (20.9) 15.8 (19.3) 20.9 (32.0)
red meat intake in g/day, median (IQR) 30.7 (25.9) 32.2 (24.6) 31.9 (29.1) 41.2 (29.9) 48.0 (39.4) 51.9 (39.3)
whole-grain bread intake in g/day, median (IQR) 31.1 (62.8) 31.4 (57.8) 28.7 (62.6) 23.1 (54.9) 14.1 (50.0) 16.0 (52.3)
coffee intake in g/day, median (IQR) 300 (300) 450 (300) 300 (450) 450 (386) 450 (300) 300 (450)
BMI in kg/m², median (IQR) 23.4 (3.85) 28.2 (3.26) 32.7 (5.30) 23.6 (2.63) 26.0 (2.52) 29.1 (3.47)
waist circumference in cm, median (IQR) 74.5 (10.0) 88.0 (7.40) 99.0 (12.5) 85.0 (8.00) 92.0 (7.00) 101 (10.3)
Biomarker
HDL-cholesterol in mmol/l, median (IQR) 1.58 (0.48) 1.45 (0.43) 1.32 (0.31) 1.42 (0.47) 1.26 (0.39) 1.18 (0.33)
LDL-cholesterol in mmol/l, mean (SD) 2.92 (0.85) 3.33 (0.98) 3.25 (0.86) 3.12 (0.88) 3.33 (0.83) 3.26 (0.97)
Triglycerides in mmol/l, median (IQR) 0.92 (0.54) 1.43 (0.80) 1.82 (1.26) 0.98 (0.57) 1.44 (0.91) 2.26 (1.55)
Total Cholesterol in mmol/l, mean (SD) 4.98 (1.04) 5.58 (1.13) 5.57 (1.05) 5.01 (1.05) 5.39 (1.00) 5.69 (1.08)
ALT in U/l, median (IQR) 15.1 (5.80) 20.9 (11.6) 24.4 (12.8) 19.9 (8.19) 25.7 (14.0) 35.1 (21.1)
GGT in U/l, median (IQR) 11.6 (6.96) 19.7 (15.1) 27.3 (27.8) 15.2 (10.5) 26.9 (23.4) 43.3 (38.0)
ALT in μkat/l, median (IQR) 0.25 (0.10) 0.35 (0.19) 0.41 (0.21) 0.33 (0.14) 0.43 (0.23) 0.59 (0.35)
GGT in μkat /l, median (IQR) 0.19 (0.12) 0.33 (0.25) 0.46 (0.46) 0.25 (0.18) 0.45 (0.39) 0.72 (0.64)
Fetuin-A in μg/ml, mean (SD) 269 (63.6) 274 (61.9) 280 (62.3) 257 (57.6) 264 (55.2) 264 (52.5)
CRP in nmol/l, median (IQR) 4.42 (11.1) 15.5 (30.9) 30.9 (44.2) 2.23 (6.69) 5.57 (11.1) 8.91 (15.6)
Adiponectin in μg/ml, median (IQR) 9.69 (5.13) 8.23 (4.85) 7.29 (3.90) 7.20 (3.92) 6.04 (3.13) 5.38 (2.94)
Glucose in mmol/l, median (IQR) 5.39 (0.79) 5.64 (0.97) 5.70 (0.91) 5.53 (0.86) 5.80 (0.95) 5.93 (1.08)
HbA1c in mmol/mol, median (IQR) 33.7 (5.79) 35.7 (7.32) 37.5 (7.32) 34.1 (5.68) 35.7 (6.78) 36.3 (8.03)
IQR, interquartile range; FLI, fatty liver index; ALT, alanine transaminase; GGT, γ-glutamyltransferase; CRP, C-reactive protein
a women: n = 1215; men: n = 707
b Sum of biking and sporting activities in h/week
doi:10.1371/journal.pone.0124749.t001
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In the age-stratified model, men in the third category (60) had a HR of 11.4 (95% CI 6.70–
19.3) (see Table 2). Adjustment for lifestyle and other socioeconomic factors showed no sub-
stantial change: HR 10.9 (95% CI 6.22–19.2). Further adjustment for BMI or waist circumfer-
ence at baseline attenuated the association between the FLI and risk of type 2 diabetes in men,
and no differences between both measures were observed [PEEBMI (95% CI) = 53.8% (43.9%–
65.8%) vs. PEEwaist (95% CI) = 54.8% (44.2%–68.8%)]. Adjustment for GGT showed no attenu-
ating effect in men. The inclusion of triglycerides resulted in a PEETG (95% CI) = 6.23 (2.03%–
11.8%) in the highest category.
Table 2. HR (95%CI) for type 2 diabetes by categories of the fatty liver index in EPIC-Potsdama.
FLI categories women FLI categories men
<30 30-<60 60 <30 30-<60 60
FLI, median (IQR)b 7.17
(10.4)
42.5 (15.2) 77.0 (22.0) 16.8
(14.5)
44.0 (13.5) 78.2 (19.1)
n (cases) 39 71 138 17 62 293
Model 1 (age-stratiﬁed) 1 7.03 (4.50–11.0) 17.1 (11.3–25.9) 1 3.05 (1.71–5.44) 11.4 (6.70–19.3)
Model 2 (multivariable-adjusted) 1 7.25 (4.51–11.7) 17.6 (11.1–28.0) 1 2.53 (1.37–4.67) 10.9 (6.22–19.2)



















































Model 2 + BMI, waist, GGT,
triglycerides









FLI, fatty liver index; PEE, Proportion of exposure effect
a women: n = 1439, men: n = 1046
b in sub-cohort
* signiﬁcant change in β-coefﬁcients compared to the multivariable-adjusted model
Model 2 is further adjusted for education (no vocational training or in training, vocational training, technical school, technical college or university),
occupation (sedentary, standing, (heavy) manual work), smoking behavior (never smoker, ex-smoker, current smoker <20 units/day, current smoker 20
units/day), sport activities (no sport, 4 h/week, >4 h/week), biking (no biking, <2.5 h/week, 2.5–4.9 h/week, 5 h/week), alcohol intake (women: no
alcohol intake, >0–6 g/day, >6–12 g/day, >12–24 g/day, >24–60 g/day, >60 g/day; men: no alcohol intake, >0–6 g/day, >6–12 g/day, >12–24 g/day, >24–
60 g/day, >60–96 g/day, >96 g/day), coffee consumption (ml/day), red meat intake (g/day), intake of whole-grain bread (g/day).
doi:10.1371/journal.pone.0124749.t002
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In sensitivity analyses, the exclusion of non-fasted or prediabetic participants or participants
with moderate or high baseline alcohol consumption or with higher lifetime alcohol consump-
tion did not affect the overall results (S1–S4 Tables).
Table 3 illustrates the results of the effect decomposition of the association between the FLI
and the type 2 diabetes risk by using the IPW-method. In women, the total HR of 3.00 was de-
composed into a direct HR for the FLI of 2.13 and an indirect HR of 1.41 which was decom-
posed into HRBMI = 1.10; HRwaist = 1.28; HRGGT = 0.97 and HRTG = 1.03. In men, the indirect
HR was decomposed into HRBMI = 1.25; HRwaist = 1.29; HRGGT = 0.97 and HRTG = 0.99,
which resulted in a total effect of 2.22×1.25×1.29×0.97×0.99 = 3.44. When waist circumference
was adjusted for BMI, it still explained a small proportion of the total effect in women (5.73%)
whereas in men, there was no effect HRwaist transformed = 0.99.
Discussion
In the present study, the FLI was associated with a higher risk of type 2 diabetes in women and
men. This association was independent of potential confounding socioeconomic and lifestyle
risk factors. Further adjustment for BMI or waist circumference attenuated this association in
men. However, in women, adjustment for BMI had no significant effect and the inclusion of
waist circumference only moderately attenuated the association. GGT and triglycerides ex-
plained only small proportions in both sexes.
Table 3. Total, direct and indirect effects with 95% CI of the association between the fatty liver index and the risk of type 2 diabetes within
EPIC-Potsdama.
waist circumference untransformed waist circumference transformed
women men women men
HR (95%
CI)








































































a women: n = 1439, men: n = 1046
The exposure was deﬁned as FLI categories (<30, 30-<60, 60); waist circumference was transformed by adding up the median waist circumference with
the residuals obtained from a linear regression of waist circumference and BMI which was adjusted for age at baseline, education (no vocational training
or in training, vocational training, technical school, technical college or university), occupation (sedentary, standing, (heavy) manual work), smoking
behavior (never smoker, ex-smoker, current smoker <20 units/day, current smoker 20 units/day), sport activities (no sport, 4 h/week, >4 h/week),
biking (no biking, <2.5 h/week, 2.5–4.9 h/week, 5 h/week), alcohol intake (women: no alcohol intake, >0–6 g/day, >6–12 g/day, >12–24 g/day, >24–60 g/
day, >60 g/day; men: no alcohol intake, >0–6 g/day, >6–12 g/day, >12–24 g/day, >24–60 g/day, >60–96 g/day, >96 g/day), coffee consumption (ml/day),
red meat intake (g/day), intake of whole-grain bread (g/day).
doi:10.1371/journal.pone.0124749.t003
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Our results of a strong positive association between the FLI, as a surrogate measure for fatty
liver, and type 2 diabetes risk are in line with other cohort studies on NAFLD and incident type
2 diabetes [4, 10, 33–43]. However, most research was conducted in Asian individuals undergo-
ing periodic health examinations [4, 33, 35–40], and only one study focused on Caucasian
(French volunteers) [10]. Similar to our results, Balkau et al. found a stronger risk relation in
women compared to men, although it was significant in both sexes [10]. Studies among Japa-
nese and Korean men were consistent with our finding, that fatty liver is an independent risk
factor for type 2 diabetes in men [34, 43]. The remaining studies showed no sex-stratified esti-
mates, however, they found fatty liver to be associated with increased risk of type 2 diabetes
within their cohorts [4, 35–42].
The adjustment for potential confounders differed between the studies. While some adjust-
ed for age, sex and lifestyle variables, others additionally included family history of diabetes or
measures of insulin resistance and all studies found an independent association between
NAFLD and incident type 2 diabetes. Contrary to the previous studies, we additionally adjusted
for dietary risk factors for type 2 diabetes. However, these factors together with other con-
founding lifestyle and socioeconomic factors had only a slight impact on the observed associa-
tion in our study. Alcohol consumption is an important factor to distinguish between NAFLD
and alcoholic fatty liver disease. Most studies excluded participants with a higher alcohol intake
and adjusted for alcohol consumption, while others only adjusted for alcohol intake—as we did
in the main analysis. However, our sensitivity analyses, excluding participants with higher alco-
hol consumption at baseline or during lifetime yielded essentially similar results.
While most previous cohort studies used ultrasound to determine fatty liver, two previous
studies used the FLI [10, 11]. However, both studies used different cut-off values when evaluat-
ing diabetes risk compared to our analysis. While we used the original categories suggested by
Bedogni et al. [8], Balkau et al. [10] did not describe their decision for using FLI<20 and FLI
70 as cut-offs. Jung et al. [11] used a lower cut-off to rule out fatty liver based on a previous
study which found that the likelihood not to have fatty liver was greater than 91% by using FLI
<20 [44]. Nevertheless, when we applied these cut-offs to our data, the results were not
markedly changed (data not shown).
In our study, the FLI was associated with diabetes risk even after adjustment for BMI and
waist circumference—two major components of the index. This is generally in line with previ-
ous studies which observed significant relations of fatty liver with diabetes after adjustment for
BMI [34, 35]. Two previous studies also considered waist circumference as covariate and—sim-
ilar to our study—found a significant increased risk for type 2 diabetes among participants
with fatty liver [41, 43]. Altogether, these findings are in agreement with data showing that
liver fat content is associated with insulin resistance and prediabetes—stronger than total and
visceral fat mass [45, 46].
We observed that single anthropometric FLI components seem to play a different role for
diabetes risk in women and men. While in men further adjustment for either BMI or waist cir-
cumference revealed a similar strong attenuation of the risk association, in women, adjustment
for BMI showed almost no effect and adjustment for waist circumference only moderately at-
tenuated the association. The results obtained from the effect decomposition method using
IPW agree with these findings. Overall this analysis suggests that the FLI provides additional
information beyond waist circumference and BMI in women, whereas in men, the observed as-
sociation with diabetes risk may mainly be driven by these two parameters. Contrary to our
findings, studies using ultrasound to assess fatty liver did not observe different attenuation of
the association with type 2 diabetes between the sexes when adjusting for BMI [33, 36].
Additionally, Feller et al. observed a negative interaction between waist circumference and
BMI in EPIC-Potsdam [47] with weaker associations between waist circumference and risk of
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type 2 diabetes at higher BMI. However, the FLI does not include an interaction term of BMI
and waist circumference; therefore, we did not model an interaction of both components in
our analysis.
While adjustment for BMI and waist circumference led to stronger attenuations, adjustment
for GGT and triglycerides—two established risk factors for type 2 diabetes—explained only
small proportions of the diabetes risk. This might be due to the fact that in the study of Bedogni
et al. [8] GGT and triglycerides were only minor predictors for fatty liver. Overall, the associa-
tion between the FLI and risk of type 2 diabetes does not seem to be mediated by these two pa-
rameters in our study.
None of the previous studies using the FLI presented sex-stratified models with and without
adjustment for its single components. Within this context, it is debatable whether the FLI for-
mula is equally suitable for women and men. The FLI does not account for sex as predictive
factor even though the prevalence of fatty liver is higher in men than in women [48, 49]. Bed-
ogni et al. [8] used bootstrapped stepwise logistic regression and tested several models to derive
the final score, including sex as predictor. However, only triglycerides, BMI, GGT and waist
circumference remained as the most predictive factors, which might indicate that waist circum-
ference captures most of the information provided by sex. Within the study of Bedogni et al.
[8] 61% of the participants were men and fatty liver was less frequent among women (34% vs.
54%). Similarly, in our study population women were less likely to have fatty liver as predicted
by the FLI. However, women with a FLI60 showed high CRP levels and therefore might have
a more progressive form of fatty liver [50] compared to the men. Consequently, sex-specific
cut-offs to predict fatty liver might be reasonable.
Our study has several limitations. Although Bedogni et al. [8] used fasting blood samples to
measure triglyceride levels and GGT, we included also non-fasted participants in our analysis.
However, it has been shown that triglyceride levels increase only modestly in response to nor-
mal food intake in the general population [51]. Additionally, in our sensitivity analysis, the ex-
clusion of non-fasted participants did not materially change the results.
Another limitation is that we could not differentiate between alcoholic fatty liver disease
and non-alcoholic fatty liver disease in our study. Nevertheless, exclusion of participants con-
suming>20 g/day (women) or>30 g/day (men) did not affect the association. Because partici-
pants might have changed their alcohol intake before the baseline examination due to
increased liver enzymes or other health problems, we accounted for lifetime alcohol consump-
tion, while previous studies only considered alcohol consumption at baseline. Indicating ro-
bustness of our findings, we observed no substantial changes in our results.
A further limitation of our study refers to the usage of the FLI as a surrogate measure for
fatty liver. In large epidemiological studies, techniques such as ultrasound or MRS are rarely
available and expensive. The FLI provided a good diagnostic accuracy for fatty liver in the orig-
inal study population (AUROC = 0.85; 95% CI 0.81–0.88). External validation studies in Ger-
man and Korean individuals found comparable AUROC values by using ultrasound [52–55].
However, especially in validation studies against MRS [9] or liver biopsy [56, 57] lower
AUROC values were obtained. Several factors such as NAFLD measurement and characteris-
tics of the study population might have contributed to that. First, the FLI was developed by
using ultrasound, thus validation studies using the same technique found a better diagnostic
accuracy. Although ultrasonography is an accurate and reliable tool to detect moderate to se-
vere fatty liver (20–30%), with a sensitivity of 84.8% and a specificity of 93.6% [58], the ability
to detect lower percentages of liver fat by ultrasound might be limited [59, 60]. Second, the FLI
was derived from a selected population in which 61.5% were male, 43.5% of the individuals
had suspected liver disease and the average BMI was 27 kg/m2.
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The strengths of our study include the prospective design, the wide assessment of potential
confounding factors and the usage of validated type 2 diabetes cases. Although the FLI can
only be interpreted as a surrogate measure for fatty liver, this index uses four variables which
can easily be obtained and therefore, the FLI might be relevant for clinical practice. However,
further investigation regarding its predictive power in women and men might be useful.
In conclusion, our data suggest that the FLI, as a proxy for fatty liver, is positively associated
with risk of type 2 diabetes. This association is only partly explained by standard estimates of
overall and abdominal body fatness, particularly among women.
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